Dr. Kurian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Palo Alto, CA 94305Phone+1 650-723-4000
Education & Training
- Stanford University School of MedicineM.Sc., 2004 - 2006
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2002 - 2003
- Massachusetts General HospitalResidency, Internal Medicine, 1999 - 2002
- Harvard Medical SchoolClass of 1999
- Stanford UniversityB.A., 1991 - 1995
Certifications & Licensure
- CA State Medical License 2002 - 2025
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples Start of enrollment: 2001 Aug 01
Publications & Presentations
PubMed
- 574 citationsGenetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021Mary B. Daly, Tuya Pal, Michael Berry, Saundra S. Buys, Patricia I. Dickson
Journal of the National Comprehensive Cancer Network. 2021-01-06 - 39 citationsGreater financial toxicity relates to greater distress and worse quality of life among breast and gynecologic cancer survivors.Catherine Benedict, Sophie Fisher, Lidia Schapira, Sabrina Chao, Sarah Sackeyfio
Psycho-Oncology. 2021-07-05 - 188 citationsChange in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic ReviewJennifer L. Caswell-Jin, Sylvia K. Plevritis, Lu Tian, Christopher J Cadham, Cong Xu
JNCI Cancer Spectrum. 2018-10-01
Journal Articles
- Association of Risk-Reducing Salpingo-Oophorectomy with Breast Cancer Risk in Women with BRCA1 and BRCA2 Pathogenic VariantsMary B Daly, Sarah Colonna, Saundra S Buys, Allison W Kurian, JAMA Oncology
- Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer—ReplyAllison W Kurian, Steven J Katz, JAMA
- From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor SequencingWilliam J Gradishar, Al B Benson, Massimo Cristofanilli, Allison W Kurian, Value in Health
- Join now to see all
Lectures
- Breast cancer treatment according to pathogenic variants in cancer susceptibility genes in a population-based cohort.ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
- Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Women’s Health Initiative.ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- Genetic testing and results in population-based breast cancer patients and ovarian cancer patients.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Authored Content
- From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor SequencingAugust 2018
Press Mentions
- Genetic Tests Provide Treatment Opportunities and Confusion for Breast Cancer PatientsOctober 21st, 2024
- Many Breast Cancer Survivors with Indications for Genetic Testing Do Not Receive ItJuly 24th, 2024
- Antibiotics After Breast Cancer Linked to Poorer Survival, Stanford Medicine-Led Study FindsApril 18th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: